Clinical Data Announces Collaboration with CombinatoRx for the Development of Novel B-Cell Cancer Therapy
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Clinical Data, Inc. has announced a collaboration and licensing agreement with CombinatoRx, Inc. to develop an adenosine A2A agonist compound in a combination therapy for the treatment of multiple myeloma, and other B-cell cancers.
Under the agreement, Clinical Data licensed its highly selective adenosine A2A agonist, ATL313, to CombinatoRx in exchange for the potential to receive up to $252 million in clinical, regulatory and commercial milestones, as well as royalties on product sales. Clinical Data also retains a co-development option, which is exercisable after review of any Phase IIa study results.
As part of the agreement, Clinical Data will contribute ATL313, a promising late-stage, preclinical compound. Under the collaboration, CombinatoRx will be responsible for the preclinical and clinical development of ATL313 to potentially treat B-cell malignancies.
Research has shown that a combination drug approach utilizing adenosine A2A agonists as a component of a combination therapy could be beneficial in the treatment of multiple myeloma. Initial results from studies utilizing this approach have been presented by CombinatoRx and demonstrated:
l broad activity in multiple myeloma cell lines
l synergy with multiple myeloma standard-of-care therapies
l potent induction of apoptosis (cancer cell death)
l selectivity and safety with broad therapeutic window over normal cells.
"Adenosine A2A agonists have shown tremendous promise in the development of therapeutics to treat a variety of diseases including cancer, inflammation, and pain disorders," said Drew Fromkin, President and CEO of Clinical Data. "We are pleased to continue to leverage the value of our highly selective adenosine pipeline by working with CombinatoRx to develop new therapies for multiple myeloma and other B-cell malignancies."
Under the agreement, Clinical Data licensed its highly selective adenosine A2A agonist, ATL313, to CombinatoRx in exchange for the potential to receive up to $252 million in clinical, regulatory and commercial milestones, as well as royalties on product sales. Clinical Data also retains a co-development option, which is exercisable after review of any Phase IIa study results.
As part of the agreement, Clinical Data will contribute ATL313, a promising late-stage, preclinical compound. Under the collaboration, CombinatoRx will be responsible for the preclinical and clinical development of ATL313 to potentially treat B-cell malignancies.
Research has shown that a combination drug approach utilizing adenosine A2A agonists as a component of a combination therapy could be beneficial in the treatment of multiple myeloma. Initial results from studies utilizing this approach have been presented by CombinatoRx and demonstrated:
l broad activity in multiple myeloma cell lines
l synergy with multiple myeloma standard-of-care therapies
l potent induction of apoptosis (cancer cell death)
l selectivity and safety with broad therapeutic window over normal cells.
"Adenosine A2A agonists have shown tremendous promise in the development of therapeutics to treat a variety of diseases including cancer, inflammation, and pain disorders," said Drew Fromkin, President and CEO of Clinical Data. "We are pleased to continue to leverage the value of our highly selective adenosine pipeline by working with CombinatoRx to develop new therapies for multiple myeloma and other B-cell malignancies."
